Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Amaryl · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Glimepiride Tablets 1 mg |
| 2 | ACTIVE_COMPARATOR | Amaryl® Tablets 1 mg |
| Name | Type | Description |
|---|---|---|
| Glimepiride Tablets 1 mg | DRUG | 1mg, single dose fasting |
| Amaryl® Tablets 1 mg | DRUG | 1mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. a. Women of childbearing potential must have a negative serum (Beta HCG) pregnancy test performed within 14 days prior to the start of the study and on the evening prior to each dose administrati...
Amaryl is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with two completed trials evaluating its pharmacokinetics. The drug is being developed by Viatris Inc. and is not yet approved for any indication.
Amaryl is being developed by Viatris Inc., a company traded on the stock exchange under the ticker VTRS. The drug is currently in Phase 1 clinical trials, and Viatris is the developer responsible for its clinical program.
Amaryl is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers. The drug is investigational and has not been approved by regulatory authorities, as it is still in the early stages of clinical testing.
Amaryl has two completed Phase 1 clinical trials: NCT00648362, a fasting study comparing glimepiride tablets 1 mg to Amaryl tablets 1 mg, and NCT00650533, a food study with the same comparison. Both trials enrolled 40 healthy volunteers each in the United States.
Amaryl is being studied in comparison to glimepiride tablets in clinical trials. The trials are designed to evaluate the pharmacokinetics of Amaryl tablets 1 mg against glimepiride tablets 1 mg under fasting and fed conditions. The drug is currently in Phase 1 development.